These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28801127)

  • 1. Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.
    Del Re M; Biasco E; Crucitta S; Derosa L; Rofi E; Orlandini C; Miccoli M; Galli L; Falcone A; Jenster GW; van Schaik RH; Danesi R
    Eur Urol; 2018 Jan; 73(1):e11-e12. PubMed ID: 28801127
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.
    De Giorgi U; Conteduca V; Scarpi E
    Eur Urol; 2018 Jan; 73(1):e9-e10. PubMed ID: 28789806
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
    Rescigno P; de Bono JS
    Eur Urol; 2016 Dec; 70(6):e170-e171. PubMed ID: 27240941
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013.
    Mehra N; Dolling D; de Bono J
    Eur Urol; 2018 Sep; 74(3):e69-e70. PubMed ID: 29866468
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
    Caffo O; Maines F; Veccia A
    Eur Urol; 2015 Dec; 68(6):e132-3. PubMed ID: 26320376
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
    Michel MC
    Eur Urol; 2017 May; 71(5):834-835. PubMed ID: 28131465
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
    van Soest RJ; de Morrée ES; Kweldam CF; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
    Eur Urol; 2016 Mar; 69(3):e43-4. PubMed ID: 26233533
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Adam G. Sowalsky, Stephen R. Plymate, Michael C. Haffner, Johann S. de Bono, and Adam Sharp's Letter to the Editor re: Heng Li, Yucong Zhang, Dong Li, et al. Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. Eur Urol 2021;79:879-86: AR-V7 is Rare in Hormone-sensitive Prostate Cancer.
    Li H; Zhang Y; Xu H
    Eur Urol; 2022 Nov; 82(5):e137-e138. PubMed ID: 36088181
    [No Abstract]   [Full Text] [Related]  

  • 9. 'Reply to the letter to the editor 'Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer' by Yang et al.' by V. Conteduca, U. De giorgi and G. Lauletta.
    Yang DD; Nguyen PL
    Ann Oncol; 2018 Sep; 29(9):2021-2022. PubMed ID: 30032198
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
    Lu K
    Eur Urol; 2015 Dec; 68(6):e129-31. PubMed ID: 26318711
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Xiao Li, Zicheng Xu, and Feng Qi's Letter to the Editor re: Soumyajit Roy, Yilun Sun, Scott C. Morgan, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Eur Urol 2023;83:571-9.
    Roy S; Sun Y; Morgan S; Malone S
    Eur Urol; 2024 Jan; 85(1):e12-e13. PubMed ID: 37596192
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
    Shiota M; Yokomizo A
    Eur Urol; 2016 Mar; 69(3):e41-2. PubMed ID: 26215602
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Isabel Heidegger, Renate Pichler, and Andreas Pircher's Letter to the Editor re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. Eur Urol 2017;71:776-87.
    Thysell E; Ylitalo EB; Jernberg E; Bergh A; Wikström P
    Eur Urol; 2017 Oct; 72(4):e104-e105. PubMed ID: 28642023
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Bernard Tombal's letter to the editor re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
    Sciarra A
    Eur Urol; 2014 Apr; 65(4):e57. PubMed ID: 24388442
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8.
    Vis AN; Boevé LMS
    Eur Urol; 2019 May; 75(5):e131-e132. PubMed ID: 30616950
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Herney Andrés García-Perdomo's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75:410-8. High-volume Disease Has a Different Standard of Care: Is Local Treatment Really Beneficial in Low-volume Metastatic Prostate Cancer?
    Boevé LMS; Vis AN
    Eur Urol; 2019 Apr; 75(4):e101-e102. PubMed ID: 30503181
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31.
    Nabid A; Souhami L
    Eur Urol; 2019 Mar; 75(3):e63. PubMed ID: 30773206
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3.
    Steinestel J; Bernemann C; Schrader AJ; Lennerz JK
    Eur Urol; 2017 Apr; 71(4):e107-e108. PubMed ID: 27647434
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostate cancer: Exosomal AR-V7 is a marker of hormonal therapy resistance.
    Fenner A
    Nat Rev Urol; 2016 Dec; 13(12):695. PubMed ID: 27779227
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Valeria Panebianco, Francesco Del Giudice, Yoshifumi Narumi, Giuseppe Simone, Ettore De Berardinis, and James Catto's Letter to the Editor re: Helena Vila-Reyes, G. Joel De Castro, and James M. McKiernan's Letter to the Editor re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020; 77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer? Eur Urol 2021;79:e35-e36.
    Vila-Reyes H; Joel DeCastro G; McKiernan JM
    Eur Urol; 2021 Feb; 79(2):e54-e55. PubMed ID: 33248798
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.